Liver-directed therapiesfor fibrolamellar carcinoma:Asingle-center experience
作者机构：Department of RadiologyMemorial Sloan Kettering Cancer Center and Weill Medical College at Cornell UniversityNew YorkNY 10065USA Department of MedicineMemorial Sloan Kettering Cancer Center and Weill Medical College at Cornell UniversityNew YorkNY 10065USA Division of Hepatobiliary SurgeryDepartment of SurgeryMemorial Sloan Kettering Cancer Center and Weill Medical College at Cornell UniversityNew YorkNY 10065USA
出 版 物：《Oncology Research》 (肿瘤学研究（英文）)
年 卷 期：2024年第32卷第12期
页 面：1831-1836页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Fibrolamellar carcinoma(FLC) Hepatocellular carcinoma(HCC) Liver-directed therapy(LDT) Transarterial radioembolization(TARE) Hepatic artery embolization
摘 要：Background:This article aims to present the single-institution outcomes of patients with Fibrolamellar Carcinoma(FLC)treated with liver-directed therapies(LDT).Methods:In this single-center retrospective study,all patients diagnosed with FLC who underwent LDT were identifi*** July 2012 and July 2023,six patients were identifi*** patient was excluded due to *** and clinical parameters were *** within 30 days of the LDT were *** treatment responses at 1,6,and 12 months were assessed per ***:A total offive patients,which included three females and two males,were *** patients were treated with transarterial hepatic embolization(TAE;n=3),transarterial radioembolization(TARE;n=1),and combined TAE+radiofrequency ablation(n=1).The objective response rate at one month was 80%[CR=2(40%),PR=2(40%),and SD=1(20%)].At 12 months(n=4),two patients demonstrated CR(50%)and two demonstrated PR(50%).Overall survival from LDT atfive years was 50%.There was no 30-day mortality among this group of patients or any adverse event attributable to the ***:TAE,TARE,and ablation are safe and effective therapeutic options for *** on this study and previously published case reports,ablation and TARE yielded the most favorable results.
维普期刊数据库
